trending Market Intelligence /marketintelligence/en/news-insights/trending/70Ppry80v2sGQ_RpugYI0w2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Teva's inhaler becomes 1st US FDA-approved digital device for a type of asthma

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Teva's inhaler becomes 1st US FDA-approved digital device for a type of asthma

Teva Pharmaceutical Industries Ltd.'s ProAir Digihaler became the first digital inhaler to be approved by the U.S. Food and Drug Administration to treat a type of asthma in children and adults.

The Israeli pharmaceutical giant said the product was approved to treat or prevent bronchospasm in patients 4 years and older with reversible obstructive airway disease and for preventing exercise-induced bronchospasm in patients 4 years and older.

Bronchospasm is a condition in which the muscles lining the airways in the lungs tighten and limit the amount of air in the lungs. About 25 million Americans have asthma, and many of them use inhalers as part of their treatment regimen, said the company.

Teva said the ProAir Digihaler inhalation powder is the first and only digital inhaler with built-in sensors that connect to a mobile application and provide inhaler-use information to people with asthma and chronic obstructive pulmonary disease.

ProAir Digihaler is an enhancement to the original ProAir, which was approved for the same use, but with a built-in electronic module and a companion mobile application.

Teva said the product will be available in 2019 through an "early experience" program that will be conducted in partnership with healthcare systems and in limited geographies.